Pacylex Presents Evidence Supporting Advancement of PCLX-001 for Treatment of AML at AACR 2022

Edmonton, Alberta--(Newsfile Corp. - April 8, 2022) - Pacylex today announced that data from an investigation of the potential for N-myristoylation inhibition to treat Acute Myeloid Leukemia (AML) will be presented at the American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. This investigation included the association of N-myristoyl transferase (NMT) expression levels with AML patient survival and the in vitro and in vivo demonstration of AML cell killing and tumor reduction with PCLX-001, a proprietary, potent, NMT inhibitor in clinical investigation in Non-Hodgkin's Lymphoma (NHL) and solid tumor cancer patients. The poster details are below:

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• New data on PCLX-001 being presented at American Association for Cancer Research (AACR) Annual Meeting.
• In vitro and animal model data shows the potential for N-myristoylation inhibition to treat for Acute Myeloid Leukemia (AML).
• PCLX-001 dramatically reduces AML stem cells in the bone marrow.

Click image above to view full announcement.

PCLX-001

PCLX-001 (aka DDD86481) is a first-in-class, small molecule NMT inhibitor originally developed by the University of Dundee Drug Discovery Unit as part of a program to treat African sleeping sickness, funded by Wellcome Trust. Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma. PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In leukemia, lymphoma and breast cancer patients, the levels of NMT2 is correlated with survival, suggesting an important biological role in these cancers. In tests using cultured cancer cells in vitro, PCLX-001 is at least ten times as potent as ibrutinib (Imbruvica) and dasatinib (Sprycel), two clinically approved drugs currently used to treat hematologic malignancies. 

About Pacylex

Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta connecting myristoylation to cancer with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex initiated clinical studies in Canada in the fall of 2021 in diffuse large B-cell lymphoma and solid tumors. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.

For more information:

Pacylex Pharmaceuticals Contact:
Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
E: michael.weickert@pacylex.com
P: 650-218-1840
Twitter @Pacylex (https://twitter.com/pacylex)
LinkedIn (www.linkedin.com/company/pacylex-pharma)
Facebook (https://www.facebook.com/pacylex)
#cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame

Contacts:

Michael Weickert Ph.D
650-218-1840
michael.weickert@pacylex.com

Source: Pacylex

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119805